Senores Pharmaceuticals Limited has filed its annual encumbrance disclosure with stock exchanges, fulfilling regulatory requirements under the Securities and Exchange Board of India (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The disclosure pertains to the financial year ended March 31, 2026, and was submitted on April 02, 2026.

Regulatory Compliance Filing

The annual disclosure was submitted pursuant to Regulation 31(4) of the SAST Regulations, which mandates promoters and promoter groups to disclose any encumbrances made on their shareholdings. Company Secretary and Compliance Officer Vinay Kumar Mishra submitted the filing to both BSE Limited and National Stock Exchange of India Limited on behalf of the company.

Promoter Declaration

Swapnil Jatinbhai Shah, promoter of Senores Pharmaceuticals Limited, submitted the disclosure on behalf of all promoters, promoter group members, and persons acting in concert. The declaration confirms that no new encumbrances were created on shares held by the promoter group during the financial year ended March 31, 2026.

Stock Exchange Submission

The disclosure was formally submitted to both major Indian stock exchanges where the company's shares are listed. The filing ensures transparency regarding promoter shareholding patterns and any potential encumbrances that could affect shareholder interests.

The company emphasized that while no new encumbrances were created during the financial year, any previously disclosed encumbrances to the stock exchanges remain on record. This annual filing represents part of the company's ongoing compliance with securities market regulations designed to protect investor interests and maintain market transparency.

Senores Pharmaceuticals Limited has announced the formation of a strategic joint venture in the United States through its wholly owned subsidiary, marking a significant expansion into the federal government procurement market. The company filed an official intimation with stock exchanges under Regulation 30 of SEBI regulations regarding the formation of step-down subsidiary Amerisyn, LLC.

Joint Venture Formation Details

The joint venture was established through Senores Pharmaceuticals, Inc. (SPI), the company's wholly owned subsidiary in the United States. According to the Operating Agreement executed on April 2, 2026, SPI has subscribed to 70% membership interest in Amerisyn, LLC, making it a step-down subsidiary of the parent company.

Strategic Market Access for Federal and Defense Sectors

This partnership strategically positions Senores to facilitate supply of its pharmaceutical product portfolio to multiple U.S. government sectors including federal government contracts, veterans affairs supply agreements, military supply contracts, and long-term national contracts. The joint venture framework provides the company with specialized credentials necessary to participate in the high-entry-barrier U.S. government procurement market, specifically targeting federal and defense needs.

Regulatory Compliance and Disclosure

The company has fulfilled its regulatory obligations by filing the required intimation with both stock exchanges. The disclosure was made under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular dated January 30, 2026.

Company Portfolio and Manufacturing Capabilities

Senores Pharmaceuticals operates as a global, research-driven pharmaceutical company with extensive manufacturing capabilities. The company's portfolio includes 46 ANDAs with 137 strengths, a pipeline of 22 ANDAs with 52 strengths, and over 450 product registrations across more than 40 countries.

The company also maintains three R&D sites, with one facility in the USA and two in India, supporting its differentiated product portfolio development across various therapeutic areas and dosage forms.